Are There Differences Between Women and Men After a Percutaneous Intervention?

Prior research has shown that women with coronary artery disease who undergo percutaneous revascularization present more comorbidities, require less aggressive treatments, have greater long-term morbidity rates and worst functional status and/or post-procedure angina.

This study used data from the CPORT-E trial (Cardiovascular Patient Outcomes Research Team Non primary Percutaneous Coronary Intervention) to assess baseline differences between sexes at 6 weeks and 9 months after the procedure.

The primary endpoint (PEP) was overall mortality at 6 weeks, while the secondary endpoint (SEP) was a composite of all-cause mortality, type Q acute myocardial infarction, and culprit vessel revascularization at 9 months.

Out of the 18,867 assessed patients, 6851 were women (36%). The women were older, more frequently of African-American origin, and had higher rates of hypertension, diabetes, heart failure, previous stroke, or peripheral vascular disease. In contrast, they had lower rates of prior angioplasty or myocardial revascularization surgery, prior myocardial infarction, and smoking.

In coronary angiography, women had more findings of single-vessel disease, and less frequently received multivessel angioplasty.

Read also: IVUS in Femoropopliteal PCI: Should We Start Using It?

While there were no differences between the PEP and the SEP, women had higher rates of bleeding, vascular repair, and repeat diagnostic catheterization. 

Significant differences were also observed in health status (measured by a Self-Assessment Questionnaire); they presented worse health status at 6 weeks and at 9 months at the expense of higher frequency of angina, worse quality of life, and physical limitations.

Conclusion

Being female was a predictor of worse health status at 6 weeks and at 9 months after angioplasty.

Dr. Andrés Rodríguez.
Member of the Editorial Board, SOLACI.org

Original Title: Sex Differences in Health Status and Clinical Outcomes After Nonprimary Percutaneous Coronary Intervention.

Reference: Pranoti G. Hiremath et al. Circ Cardiovasc Interv. 2022;15:e011308.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...